498 related articles for article (PubMed ID: 15824739)
1. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
3. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study.
Hadjinicolaou AV; van Munster SN; Achilleos A; Santiago Garcia J; Killcoyne S; Ragunath K; Bergman JJGHM; Fitzgerald RC; di Pietro M
EBioMedicine; 2020 Jun; 56():102765. PubMed ID: 32460165
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors.
Jin Z; Cheng Y; Olaru A; Kan T; Yang J; Paun B; Ito T; Hamilton JP; David S; Agarwal R; Selaru FM; Sato F; Abraham JM; Beer DG; Mori Y; Shimada Y; Meltzer SJ
Int J Cancer; 2008 Nov; 123(10):2331-6. PubMed ID: 18729198
[TBL] [Abstract][Full Text] [Related]
5. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.
Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
J Pathol; 2006 Jan; 208(1):100-7. PubMed ID: 16278815
[TBL] [Abstract][Full Text] [Related]
6. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
[TBL] [Abstract][Full Text] [Related]
7. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
[TBL] [Abstract][Full Text] [Related]
8. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
Hamilton JP; Sato F; Jin Z; Greenwald BD; Ito T; Mori Y; Paun BC; Kan T; Cheng Y; Wang S; Yang J; Abraham JM; Meltzer SJ
Clin Cancer Res; 2006 Nov; 12(22):6637-42. PubMed ID: 17121882
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.
Jin Z; Mori Y; Yang J; Sato F; Ito T; Cheng Y; Paun B; Hamilton JP; Kan T; Olaru A; David S; Agarwal R; Abraham JM; Beer D; Montgomery E; Meltzer SJ
Oncogene; 2007 Sep; 26(43):6332-40. PubMed ID: 17452981
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic TriModal imaging and biomarkers for neoplasia conjoined: a feasibility study in Barrett's esophagus.
Boerwinkel DF; Di Pietro M; Liu X; Shariff MK; Lao-Sirieix P; Walker CE; Visser M; O' Donovan M; Kaye P; Bergman JJ; Fitzgerald RC
Dis Esophagus; 2014 Jul; 27(5):435-43. PubMed ID: 23067399
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis.
Jin Z; Mori Y; Hamilton JP; Olaru A; Sato F; Yang J; Ito T; Kan T; Agarwal R; Meltzer SJ
Cancer; 2008 Jan; 112(1):43-9. PubMed ID: 17999418
[TBL] [Abstract][Full Text] [Related]
12. MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma.
Jin Z; Wang L; Zhang Y; Cheng Y; Gao Y; Feng X; Dong M; Cao Z; Chen S; Yu H; Zhao Z; Zhang X; Liu J; Mori Y; Fan X; Meltzer SJ
Sci Rep; 2013 Oct; 3():2838. PubMed ID: 24088706
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
14. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
15. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
[TBL] [Abstract][Full Text] [Related]
16. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA
Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary adenocarcinomas of the small bowel.
Brücher BL; Geddert H; Langner C; Höfler H; Fink U; Siewert JR; Sarbia M
Int J Cancer; 2006 Sep; 119(6):1298-302. PubMed ID: 16619216
[TBL] [Abstract][Full Text] [Related]
18. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer.
Jin Z; Olaru A; Yang J; Sato F; Cheng Y; Kan T; Mori Y; Mantzur C; Paun B; Hamilton JP; Ito T; Wang S; David S; Agarwal R; Beer DG; Abraham JM; Meltzer SJ
Clin Cancer Res; 2007 Nov; 13(21):6293-300. PubMed ID: 17975140
[TBL] [Abstract][Full Text] [Related]
20. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma.
Oshimo Y; Oue N; Mitani Y; Nakayama H; Kitadai Y; Yoshida K; Ito Y; Chayama K; Yasui W
Pathobiology; 2004; 71(3):137-43. PubMed ID: 15051926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
